In an interview on the Value: After Hours podcast with hosts Tobias Carlisle and Jake Taylor, David Ferreiro, Ph.D., Portfolio Manager & Research Analyst at TimesSquare, discusses the firm’s quality growth approach to small cap investing, how TimesSquare defines quality in biotech and broader healthcare, and where artificial intelligence is, and is not yet, changing drug development.
Drawing on his background as a scientist, David explains how TimesSquare pairs rigorous fundamental research with strong management teams, disciplined position sizing, and price-target-driven sell discipline to take educated risks in healthcare while managing downside.
Summary
David explains TimesSquare’s vehicle-agnostic, quality growth approach, which starts with the merits of the business and its management team before turning to valuation.
Key Takeaways
Summary
David describes his path from a Ph.D. in microbiology and immunology to the sell side and ultimately the buy side, and how scientific training shapes his investment process.
Key Takeaways
Summary
Using Mirum Pharmaceuticals as an example, David outlines how TimesSquare applies its quality lens to biotech by favoring later-stage and commercial companies.
Key Takeaways
Summary
David discusses why opportunities persist in biotech, pointing to uncertainty around rare disease markets and the inherent unpredictability of biology.
Key Takeaways
Summary
David explains how TimesSquare sizes healthcare positions according to their risk profile while maintaining a diversified portfolio.
Key Takeaways
Summary
David examines how interest rates and recent market rotation have affected healthcare, and where valuations look compelling.
Key Takeaways
Summary
David assesses AI’s impact on biopharma, noting meaningful efficiency gains in early-stage discovery but limited progress so far in improving the underlying biology.
Key Takeaways
Summary
David details how upside, downside, and base case price targets inform TimesSquare’s sell decisions.
Key Takeaways
Summary
David breaks down the drivers of clinical trial costs, from intensive patient monitoring to complex global logistics.
Key Takeaways
Summary
David highlights the characteristics frequently shared by biopharma companies that are acquired, including names that have come out of TimesSquare’s portfolio.
Key Takeaways
Summary
Responding to a listener question on Revolution Medicines, David discusses what it takes for a breakthrough therapy to sustain growth and how long drug exclusivity typically lasts.
Key Takeaways
Summary
David explains why TimesSquare has grown more constructive on medical technology after a period when investors avoided the sector amid GLP-1 enthusiasm.
Key Takeaways
TimesSquare’s approach to small cap healthcare investing combines scientific expertise, independent fundamental research, and a disciplined framework for sizing and exiting positions. By favoring high-quality businesses with strong management teams and real commercial foundations, the firm seeks to take educated risks in areas of innovation while working to deliver attractive long-term, risk-adjusted returns.
Specific investments described herein do not represent all investment decisions made by the Firm. The reader should not assume that investment decisions identified and discussed were or will be profitable. Specific investment advice references provided herein are for illustrative purposes only and are not necessarily representative of investments that will be made in the future.
This podcast does not constitute advice or a recommendation or offer to sell or a solicitation to deal in any security or financial product. It is provided for information purposes only and on the understanding that the recipient has sufficient knowledge and experience to be able to understand and make their own evaluation of the proposals and services described herein; any risks associated therewith; and any related legal, tax, accounting or other material considerations. To the extent that the reader has any questions regarding the applicability of any specific issue discussed above to their specific portfolio or situation, prospective investors are encouraged to contact TimesSquare Capital Management, LLC and/or consult with the professional adviser of their choosing.
The views and opinions expressed by David Ferreiro, Ph.D., during this podcast are those of the speaker and do not necessarily reflect the views, opinions, or investment positions of TimesSquare Capital Management, LLC.
Past performance does not guarantee future results.
Click here for the strategy's Top Ten Holdings.
For the TimesSquare Glossary, please visit here.